Genelux
Key Highlights
- Genelux's proprietary ChoiceTM Discovery Platform has produced over 500 versions of the vaccinia virus, showcasing its innovative approach to oncolytic immunotherapy.
- The company's lead product candidate, Olvi-Vec, is currently in a Phase 3 clinical trial for Platinum-Resistant/Refractory Ovarian Cancer, highlighting its focus on treating difficult-to-treat cancers.
- Genelux is also developing Olvi-Vec for Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and recurrent Ovarian Cancer, demonstrating its broad therapeutic potential.
- The company's mission is to deliver the full complement of tumor neo-antigens to stimulate a personalized immune response, which could significantly impact cancer treatment outcomes.
- Genelux's commitment to advancing next-generation oncolytic immunotherapies positions it as a leader in the field of cancer treatment innovation.
About Genelux
Genelux Corporation (NASDAQ: GNLX), founded in 2001, is a late clinical-stage biotechnology company based in Westlake Village, California. The company is dedicated to improving the lives of patients with difficult-to-treat solid tumors, utilizing its proprietary ChoiceTM Discovery Platform to develop oncolytic immunotherapies. Its lead product candidate, Olvi-Vec, is in a Phase 3 clinical trial for Platinum-Resistant/Refractory Ovarian Cancer and is also being developed for Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and recurrent Ovarian Cancer. Genelux aims to advance a pipeline of next-generation oncolytic immunotherapies that stimulate a personalized immune response.
Genelux's innovative approach involves creating over 500 versions of the vaccinia virus to deliver the full complement of tumor neo-antigens. This strategy is designed to enhance the body's natural immune response against cancer. The company's commitment to research and development is evident in its ongoing clinical trials and its focus on delivering effective treatments for aggressive and difficult-to-treat cancers.
For more information about Genelux's investigational products and clinical trials, visit Genelux's website. Follow updates on Twitter @Genelux_Corp and Facebook @Genelux. Note that Olvi-Vec is an investigational product candidate not yet approved by the US Food and Drug Administration.
Why Contact Genelux?
B2B professionals should contact Genelux for potential partnerships in oncolytic immunotherapy development and for vendor opportunities in biotechnology. Genelux's innovative approach and focus on difficult-to-treat cancers make it an attractive partner for companies looking to advance cancer treatment solutions.
Who Should Contact Genelux for Business?
Sales teams selling biotechnology products, recruiters seeking roles in oncology and immunotherapy research, and partners offering capabilities in clinical trial development should reach out to Genelux.
Categories
- Genelux
- Oncolytic Immunotherapy
- Vaccinia Virus
- Solid Tumors
- Clinical Trials
- Cancer Treatment
- Personalized Immune Response
- Biotechnology
- Olvi-Vec
- Phase 3 Trial
More Biotechnology Companies
Frequently Asked Questions
- How many employees does Genelux have?
- Genelux has approximately 32 employees.
- Where is Genelux headquartered?
- Westlake Village, California, United States of America
- What industry is Genelux in?
- Genelux operates in Biotechnology, Oncology, Clinical Trials.
- When was Genelux founded?
- Genelux was founded in 2001.
- What is the email format at Genelux?
- Genelux uses the email format first@genelux.com.
- Is Genelux still active?
- Yes, Genelux was verified as an active company on February 2, 2026. Data Surfer regularly validates company information to ensure accuracy.
- How do I sell to Genelux?
- Research Genelux's priorities and goals, identify the right decision makers and champions, monitor for buying signals, and reach out at the right time with verified contact details. Learn how Data Surfer helps.
Ready to Sell to Genelux?
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Backed by startup programs from
Connect with Genelux